• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Mount Sinai's Dr. Reddy demonstrates cost-effectiveness of Watchman device
(The Mount Sinai Hospital / Mount Sinai School of Medicine) Long-term analysis shows cost-effectiveness of WATCHMAN left atrial appendage closure device over warfarin and NOACs in reducing stroke risk in non-valvular atrial fibrillation patients.
Source: EurekAlert! - Medicine and Health - December 21, 2015 Category: Global & Universal Source Type: news

Cost-Effectiveness of Apixaban Versus Other New Oral Anticoagulants And Warfarin for Stroke Prevention In Atrial Fibrillation In Venezuela
Apixaban (5 mg BID), dabigatran (150mg), and rivaroxaban (20 mg once daily) are 3 novel oral anticoagulants (NOACs) currently approved for stroke prevention in patients with atrial fibrillation (AF). Although warfarin remains the standard of care in Venezuela.
Source: Value in Health - October 23, 2015 Category: Global & Universal Authors: Y Fernández Ávila, KC Garcia, S Garrido Lecca, BM Donato, A Juarez-Garcia Source Type: research

Cost-Effectiveness of Apixaban Versus Other Noacs And Warfarin, During Hospitalization In The Private Brazilian Health System
Atrial fibrillation (AF) is the most common arrhythmia in the world and it affects around 1% of the world´s population. There are approximately 1.5 million people, in Brazil, that have AF. AF is the fifth cause of hospitalization in the Public Health System. AF patients have an increased risk of developing an ischemic stroke than patients without AF. Current treatment for AF are vitamin K antagonist (AVKs), antiplatelet agents, acetylsalicylic acid (AAS) and the Oral Anticoagulants – NOACs (rivaroxaban, dabigatran and apixaban).
Source: Value in Health - October 23, 2015 Category: Global & Universal Authors: S Tanaka, MC Preto, G Bernardino, F Nogueira, CN Ferreira, BM Donato Source Type: research

Network Meta-Analysis of Oral Anticoagulants for Primary Prevention, Treatment and Secondary Prevention of Venous Thromboembolic Disease, and for Prevention of Stroke in Atrial Fibrillation
To determine the best oral anticoagulant(s) across four medical conditions: stroke prevention in atrial fibrillation (AF), primary prevention of venous thromboembolic disease (VTE), acute treatment of VTE, and secondary prevention of VTE; using network meta-analysis to compare novel oral anticoagulants (NOACs) with warfarin and/or low molecular weight heparin (LMWH).
Source: Value in Health - October 23, 2015 Category: Global & Universal Authors: JA Lopez-Lopez, J Sterne, PN Bodalia, PA Bryden, P Davies, GN Okoli, H Thom, DM Caldwell, S Dias, D Eaton, J Higgins, W Hollingworth, C Salisbury, J Savovic, R Sofat, A Stephens-Boal, NJ Welton, A Hingorani Source Type: research

Relationship of Time in Therapeutic Range (Ttr) with Bleeding and Stroke Incidences of Warfarinised Patients with Pulmonary Embolism in a Tertiary Hospital in Malaysia
This study aims to compare time in therapeutic range (TTR) of warfarin in patients with pulmonary embolism with bleeding and stroke and determine reasons of INR falling out of range.
Source: Value in Health - October 23, 2015 Category: Global & Universal Authors: N Sudirman, S Shaharuddin, CM Long, R Hashim, HH Zulkifly, SS Kasim, CW Lim Source Type: research

Preliminary Study of Safety and Efficacy of Warfarin Versus Dabigatran in Atrial Fibrillation Patients in a Tertiary Hospital in Malaysia
This study aims to compare the pattern of anticoagulants used and to assess their safety and efficacy by evaluating bleeding and stroke occurrences in both groups.
Source: Value in Health - October 23, 2015 Category: Global & Universal Authors: M Mohd Hajiri, S Shaharuddin, CM Long, R Hashim, HH Zulkifly, SS Kasim, CW Lim Source Type: research

Cost-Effectiveness Of Edoxaban Compared With Warfarin For The Prevention Of Stroke And Systemic Embolic Events In The Uk
This evaluation aimed to assess the cost-effectiveness of edoxaban 60mg versus warfarin for the prevention of stroke and systemic embolic events among patients with non-valvular atrial fibrillation (NVAF) in the UK, from the perspective of the NHS.
Source: Value in Health - October 23, 2015 Category: Global & Universal Authors: M Taylor, L Claxton, L Lewis, AE Harrington, AF Alexandre, A Bakhai, B Brueggenjuergen Source Type: research

Resource Utilisation And Bleeding Events During Anticoagulation Treatment: Real-World Findings From England
This study aimed to estimate the association between healthcare resource use and subsequent bleeding in NVAF patients prescribed VKA in England.
Source: Value in Health - October 23, 2015 Category: Global & Universal Authors: S Lister, C Lefevre, I Menown, R Alikhan, L Lacoin, A Bird, M You, E Ridha, D Evans Source Type: research

Estimation of the cost-effectiveness of apixaban versus vitamin K antagonists in the management of atrial fibrillation in Argentina
Abstract Apixaban, a novel oral anticoagulant which has been approved for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation, reduces both ischemic and haemorrhagic stroke and produces fewer bleedings than vitamin K antagonist warfarin. These clinical results lead to a decrease in health care resource utilization and, therefore, have a positive impact on health economics of atrial fibrillation. The cost-effectiveness of apixaban has been assessed in a variety of clinical settings and countries. However, data from emergent markets, as is the case of Argentina, are still scarce. ...
Source: Health Economics Review - June 26, 2015 Category: Global & Universal Source Type: research

Cost-Effectiveness and Cost-Utility Analyses of Dabigatran Compared with Warfarin in Patients with Nonvalvular Atrial Fibrillation and Risk Factors for Stroke and Systemic Embolism within Brazilian Private and Public Health Care Systems Perspectives
Conclusions Dabigatran use improves patient survival and quality of life compared with warfarin. This represents the best therapeutic option in terms of cost and effectiveness in the prevention of ischemic stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
Source: Value in Health Regional Issues - June 10, 2015 Category: Global & Universal Source Type: research

A Conservative Approach To Assess Warfarin Time-In-Therapeutic Ranges Among Nonvalvular Atrial Fibrillation Patients In An Integrated Healthcare Delivery System Setting In The U.S
This study evaluated warfarin TTRs among nonvalvular atrial fibrillation (NVAF) patients treated in an integrated healthcare delivery system (IDHS) setting.
Source: Value in Health - May 1, 2015 Category: Global & Universal Authors: S. Deitelzweig, M. Evans, E. Hillson, J. Trocio, A. Bruno, W. Tan, M. Lingohr-Smith, J. Lin Source Type: research

Cost Effectiveness Analysis Of Apixaban Compared To Oral Anticoagulants In The Prevention Of Thromboembolic Events In Patients With Non-Valvular Atrial Fibrillation In Guatemala In 2014
Atrial fibrillation (AF) is associated with development of thromboembolic events [1]. The standard therapy used in patients with non-valvular atrial fibrillation (NVAF) with risk of stroke is Warfarin. There are new oral anticoagulants (NOACs) that also are recommended [2].
Source: Value in Health - May 1, 2015 Category: Global & Universal Authors: M. Garita-Aguilar, M. Peralta-Acon, L. Jiménez-Crespo Source Type: research

Economic Evaluation Of Dabigatran Etexilate Versus Warfarin, Rivaroxaban And Apixaban In Stroke Prevention In Atrial Fibrilation
To determine the economic value of dabigatran for stroke prevention in atrial fibrillation (SPAF) compared to other reimbursed oral anticoagulants warfarin, rivaroxaban and apixaban from a perspective of Mexican public institutions.
Source: Value in Health - May 1, 2015 Category: Global & Universal Authors: J.L. Huicochea-Bartelt, J. Gay-Molina, L.A. Ortiz-Blas, S. Herran Source Type: research

Estimating the cost-effectiveness of left Atrial Appendage closure compared to warfarin for stroke prevention in Atrial Fibrillation
The objective of this study was to evaluate the cost-effectiveness of LAA closure relative to chronic warfarin therapy for stroke prevention in AF patients at elevated stroke risk.
Source: Value in Health - May 1, 2015 Category: Global & Universal Authors: V. Shih, B. Devine Source Type: research

Cost effectiveness of left atrial appendage closure versus Warfarin for stroke risk reduction in non-valvular Atrial Fibrillation in CMS patients
Stroke is the most severe and debilitating consequence of atrial fibrillation (AF), with many patients ranking the resultant disability as worse than death. Warfarin, the established first-line therapy, is effective at reducing ischemic stroke, but is associated with increased bleeding risk and lower quality of life (QoL). Left atrial appendage closure (LAAC) with the Watchman Device has been found to be superior to warfarin at reducing risk of stroke in AF patients. This analysis sought to assess the cost effectiveness of LAAC versus warfarin for stroke prevention in non-valvular AF from the perspective of the US Centers ...
Source: Value in Health - May 1, 2015 Category: Global & Universal Authors: V. Reddy, R. Akehurst, S.L. Amorosi, S. Armstrong, S. Beard, C. Knight, C. Taggart, D. Holmes Source Type: research

Pages: 1  2  3  4